目的 探討固本咳喘膠囊聯(lián)合吸入用異丙托溴銨溶液治療慢性支氣管炎的臨床療效。方法 選取2015年1月-2016年12月在西電集團(tuán)醫(yī)院進(jìn)行治療的慢性支氣管炎患者100例為研究對(duì)象，根據(jù)其不同的治療方法將患者分為對(duì)照組（48例）和治療組（52例）。對(duì)照組霧化吸入吸入用異丙托溴銨溶液，2 mL/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服固本咳喘膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組的癥狀評(píng)分、血清指標(biāo)、血?dú)庵笜?biāo)和癥狀消失時(shí)間。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為77.08%、96.15%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組咳嗽評(píng)分、咳痰評(píng)分、氣喘評(píng)分、總評(píng)分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組IgA、IgG水平明顯升高，TNF-α、IL-6水平明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組pH值、氧分壓（pO₂）水平明顯升高，二氧化碳分壓（pCO₂）水平明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組喘息、咳嗽、咳痰消失時(shí)間均短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 固本咳喘膠囊聯(lián)合吸入用異丙托溴銨溶液治療慢性支氣管炎具有較好的臨床療效，可明顯改善臨床癥狀，降低患者炎性水平，調(diào)節(jié)患者免疫功能，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Guben Kechuan Capsules combined with Ipratropium Bromide Solution for inhalation in treatment of chronic bronchitis. Methods Patients (100 cases) with chronic bronchitis in Xian XD Group Hospital from January 2015 to December 2016 were enrolled in this study. According to different treatment plans, patients were divided into the control group (48 cases) and the treatment group (52 cases). Patients in the control group were aerosol inhalation administered with Ipratropium Bromide Solution for inhalation, 2 mL/time, twice daily. Patients in the treatment group were po administered with Guben Kechuan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and symptom scores, serum indexes, blood gas indexes, and symptom disappearance time in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.08% and 96.15%, respectively, and there was difference between two groups (P<0.05). After treatment, cough score, expectoration score, asthma score, and total score in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the IgA and IgG in two groups were significantly increased, but the levels of TNF-α and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the pH value and pO₂ in two groups were significantly increased, but the levels of pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the disappearance times of wheezing, coughing and expectoration in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). Conclusion Guben Kechuan Capsules combined with Ipratropium Bromide Solution for inhalation has clinical curative effect in treatment of chronic bronchitis, can significantly improve clinical symptom, decrease the inflammatory level, and regulate the immune function, with good safety, which has a certain clinical application value.